Ignite Creation Date:
2024-05-05 @ 9:34 PM
Last Modification Date:
2024-10-26 @ 10:06 AM
Study NCT ID:
NCT00919282
Status:
COMPLETED
Last Update Posted:
2009-06-12
First Post:
2009-06-09
Brief Title:
Gemcitabine GFF in Patients With Pancreatic Cancer
Sponsor:
CONKO-Studiengruppe
Organization:
CONKO-Studiengruppe
Study Overview
Official Title:
A Multi Center Phase II Study of 5-Fluorouracil Folinic Acid Plus Gemcitabine in Patients With Advanced Pancreatic Cancer
Status:
COMPLETED
Status Verified Date:
2009-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
GFF
Brief Summary:
The purpose of this study is to examine the efficacy and safety of the drug combination GFF in patients with advanced pancreatic cancer APC
Detailed Description:
This open-label multi center phase II study was conducted to investigate the efficacy and safety of the combination of 5-Fluorouracil 5-FUfolinic acid FA plus gemcitabine GFF in patients pts with advanced pancreatic cancer APC We consequently started this study after completing the phase I trial accomplished by our CONKO- study group
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None